The weather is getting cooler, but biotech’s recovery is heating up. After a years-long wait-and-see game exhausted many ...

Andrew Miller has quickly made his first move after the technology he invented, KarXT, secured an FDA approval last week. The ...

Sanofi is offloading its rare autoimmune disease medicine Enjaymo to an Italian pharmaceutical company for $825 million ...

DRI Healthcare Trust is paying $57 million upfront to the gene editing company in exchange for future licensing payments from Vertex, which struck an agreement with Editas to use its CRISPR/Cas9 gene ...

Eli Lilly’s blockbuster GLP-1 drug tirzepatide is finally back on track in the US after two years of intermittent shortages ...

WuXi AppTec and WuXi Biologics are reportedly looking to sell part of their operations that have struggled because of ...

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...

The FDA's Center for Drug Evaluation and Research on Wednesday officially launched a new center of excellence to better ...

The UK’s publicly funded healthcare system has proposed phasing its rollout of Eli Lilly’s weight loss treatment tirzepatide ...

Flagship Pioneering's roots in Singapore are growing less than a year after the biotech incubator first unveiled its ...

The FDA greenlighted Bristol Myers Squibb’s Opdivo for use before and after surgery for non-small cell lung cancer. A regimen ...

Novo Nordisk and Eli Lilly, whose obesity drugs are some of the most in-demand drugs in the US, have drafted plans to avoid ...